Evidence map›Paper›PMID 29623961›Full record

ArticleCancer convergence2017

Distinguishing mechanisms underlying EMT tristability.

Dongya Jia, Mohit Kumar Jolly, Satyendra C Tripathi, Petra Den Hollander, Bin Huang, Mingyang Lu, Muge Celiktas, Esmeralda Ramirez-Peña, Eshel Ben-Jacob, José N Onuchic and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer convergence, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. A computational approach for perturbation-induced EMT transitions.NPJ systems biology and applications · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Tumour Stem Cells in Breast Cancer.International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Dongya Jia1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
Mohit Kumar Jolly1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
Satyendra C Tripathi7Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Petra Den Hollander8Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Bin Huang1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
Mingyang Lu1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
Muge Celiktas7Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Esmeralda Ramirez-Peña8Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Eshel Ben-Jacob1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
José N Onuchic1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
Samir M Hanash7Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Sendurai A Mani8Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA.
Herbert Levine1Center for Theoretical Biological Physics, Rice University, Houston, TX 77005 USA.
The University of Texas MD Anderson Cancer Center · USRice University · USCenter for Theoretical Biological Physics · USTel Aviv University · IL

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI William Carl Skarnes · 1985 to 2026
$61.9M
NCI NIH HHS P30 CA034196
6 · The paper itself

Abstract

backgroundThe Epithelial-Mesenchymal Transition (EMT) endows epithelial-looking cells with enhanced migratory ability during embryonic development and tissue repair. EMT can also be co-opted by cancer cells to acquire metastatic potential and drug-resistance. Recent research has argued that epithelial (E) cells can undergo either a partial EMT to attain a hybrid epithelial/mesenchymal (E/M) phenotype that typically displays collective migration, or a complete EMT to adopt a mesenchymal (M) phenotype that shows individual migration. The core EMT regulatory network - miR-34/SNAIL/miR-200/ZEB1 - has been identified by various studies, but how this network regulates the transitions among the E, E/M, and M phenotypes remains controversial. Two major mathematical models - ternary chimera switch (TCS) and cascading bistable switches (CBS) - that both focus on the miR-34/SNAIL/miR-200/ZEB1 network, have been proposed to elucidate the EMT dynamics, but a detailed analysis of how well either or both of these two models can capture recent experimental observations about EMT dynamics remains to be done.

resultsHere, via an integrated experimental and theoretical approach, we first show that both these two models can be used to understand the two-step transition of EMT - E→E/M→M, the different responses of SNAIL and ZEB1 to exogenous TGF-β and the irreversibility of complete EMT. Next, we present new experimental results that tend to discriminate between these two models. We show that ZEB1 is present at intermediate levels in the hybrid E/M H1975 cells, and that in HMLE cells, overexpression of SNAIL is not sufficient to initiate EMT in the absence of ZEB1 and FOXC2.

conclusionsThese experimental results argue in favor of the TCS model proposing that miR-200/ZEB1 behaves as a three-way decision-making switch enabling transitions among the E, hybrid E/M and M phenotypes.

Indexed as

Cascading bistable switchesCBSEMTEpithelial-Mesenchymal transitionFOXC2TCSTernary chimera switchZEB1

Identifiers

PMID29623961
PMCPMC5876698
OpenAlexW2949145420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.